{"filing":{"accession_number":"0001437749-26-033175","cik":"0001787740","ticker":"VBIO","company_name":"Valion Bio, Inc.","form":"8-K","filing_date":"2026-10-22","report_date":"2026-10-21","primary_document":"vbio20261021_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1787740/000143774926033175/vbio20261021_8k.htm"},"events":[{"id":37060,"run_id":34160,"accession_number":"0001437749-26-033175","anchor_item_number":"8.01","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.72,"summary":"The filing discloses Dean Zikria's first 30-day assessment as interim CEO, outlining strategic priorities for clinical development, commercialization, and evaluation of strategic opportunities for Velocity Bioworks. While this is primarily a governance matter (leadership communication and strategic direction), it does not fit neatly into the specific governance categories (exec_appointment, exec_departure, exec_compensation, or shareholder_vote_results). The disclosure is material because it signals a significant strategic shift under new interim leadership, including potential M\u0026A activity for Velocity, which would affect investor assessment of the company's direction and value creation prospects.","company_name":"Valion Bio, Inc.","ticker":"VBIO","filing_date":"2026-10-22","form":"8-K","submitted_at":null,"items":[{"id":41646,"accession_number":"0001437749-26-033175","item_number":"8.01","item_title":"Other Matters.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.72,"reasoning":"The filing discloses Dean Zikria's first 30-day assessment as interim CEO, outlining strategic priorities for clinical development, commercialization, and evaluation of strategic opportunities for Velocity Bioworks. While this is primarily a governance matter (leadership communication and strategic direction), it does not fit neatly into the specific governance categories (exec_appointment, exec_departure, exec_compensation, or shareholder_vote_results). The disclosure is material because it signals a significant strategic shift under new interim leadership, including potential M\u0026A activity for Velocity, which would affect investor assessment of the company's direction and value creation prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T12:01:50.068879+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41646,"accession_number":"0001437749-26-033175","item_number":"8.01","item_title":"Other Matters.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.72,"reasoning":"The filing discloses Dean Zikria's first 30-day assessment as interim CEO, outlining strategic priorities for clinical development, commercialization, and evaluation of strategic opportunities for Velocity Bioworks. While this is primarily a governance matter (leadership communication and strategic direction), it does not fit neatly into the specific governance categories (exec_appointment, exec_departure, exec_compensation, or shareholder_vote_results). The disclosure is material because it signals a significant strategic shift under new interim leadership, including potential M\u0026A activity for Velocity, which would affect investor assessment of the company's direction and value creation prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T12:01:50.068879+00:00","company_name":"Valion Bio, Inc.","ticker":"VBIO","filing_date":"2026-10-22"}]}